Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Systematic Assessment of Difficult-to-Treat Asthma: Principles and Perspectives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Development of the International Severe Asthma Registry (ISAR): a modified Delphi study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Reply to Crépeaux et al and Blasco

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  5. Effects of Exercise and Diet in Nonobese Asthma Patients-A Randomized Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Male fertility before and after androgen abuse

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Desloratadine is a frequently used drug for the treatment of allergic disorders, which often also require treatment during pregnancy. However, information on the fetal safety of desloratadine use during pregnancy is limited.

OBJECTIVE: To investigate the association between desloratadine use during pregnancy and adverse fetal outcomes.

METHODS: From a cohort of 1,287,668 pregnancies identified in the Danish nationwide registries in the study period 2001 to 2016, users of desloratadine and loratadine during pregnancy were matched in a 1:1 ratio based on propensity scores to compare the risk of adverse fetal outcomes. We compared the risk of the primary outcomes major birth defects (among a total of 3348 pregnancies) and spontaneous abortion (5498 pregnancies) and the secondary outcomes preterm birth (5280 pregnancies), small size for gestational age (SGA) for birth weight (5436 pregnancies), and stillbirth (6776 pregnancies). Logistic regression was used to estimate the prevalence odds ratio (OR) of major birth defects, preterm birth, and SGA, and Cox regression to estimate the hazard ratio (HR) of spontaneous abortion and stillbirth. Sensitivity analyses included comparing with cetirizine use in pregnancy and with pregnancies unexposed to desloratadine but with prior use as additional comparator groups.

RESULTS: Use of desloratadine in pregnancy was not associated with a significant increased risk of major birth defects (prevalence OR, 1.07; 95% confidence interval [CI], 0.77-1.50), spontaneous abortion (HR, 1.15; 95% CI, 0.96-1.37), preterm birth (prevalence OR, 0.84; 95% CI, 0.67-1.05), SGA (prevalence OR, 0.97; 95% CI, 0.80-1.16), or stillbirth (HR, 0.91; 95% CI, 0.31-2.70) compared with loratadine use in pregnancy. Sensitivity analyses, including those with the use of additional comparator groups, showed similar results.

CONCLUSION: Use of desloratadine during pregnancy was not associated with a statistically significant increased risk of adverse fetal outcomes as compared with loratadine. Results indicate that the fetal safety profile of desloratadine is similar to the currently recommended second-generation antihistamines during pregnancy.

OriginalsprogEngelsk
TidsskriftThe journal of allergy and clinical immunology. In practice
Vol/bind8
Udgave nummer5
Sider (fra-til)1598-1605
Antal sider8
ISSN2213-2198
DOI
StatusUdgivet - maj 2020

Bibliografisk note

Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

ID: 59565347